7464-93-9

Usage

Uses

1,3,9-trimethyluric acid is used as a research compound for studying the metabolism of caffeine and its effects on the human body. It can be used in scientific research to understand the metabolic pathways and the role of caffeine in various physiological processes. Additionally, it may be used as a reference compound in the development of analytical methods for the detection and quantification of caffeine and its metabolites in biological samples.

Purification Methods

Crystallise it from water and dry it at 100o in a vacuum. [Beilstein 26 H 530, 26 II 301, 26 III/IV 2623.]

InChI:InChI=1/C8H10N4O3/c1-10-5-4(9-7(10)14)6(13)12(3)8(15)11(5)2/h1-3H3,(H,9,14)

Upstream product

• 60-29-7 diethyl ether 
• 944-73-0 1,3-dimethyluric acid 
• 74-88-4 methyl iodide 
• 854824-36-5 7-acetyl-1,3,9-trimethyl-uric acid 
• 519-32-4 isocaffeine 
• 173038-83-0 4,5-dimethoxy-1,3,9-trimethyl-tetrahydro-purine-2,6,8-trione 
• 10034-85-2 hydrogen iodide 
• 64-19-7 acetic acid 
• 77-78-1 dimethyl sulfate 
• 138524-01-3 8-methoxy-1,3,9-trimethyl-3,9-dihydro-purine-2,6-dione 
• 80-48-8 methyl p-toluene sulfonate 
• 13992-53-5 1,3-dimethyl-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione 
• 6972-27-6 1,3-Dimethyl-6-chlorouracil 
• 769-42-6 1,3-dimethylbarbituric acid 

Downstream Products

• 7026-71-3 7-benzyl-1,3,9-trimethyl-7,9-dihydro-3H-purine-2,6,8-trione 
• 2309-49-1 theacrine 
• 1335009-82-9 N-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(1,3,9-trimethyl-2,6,8-trioxo-1,2,3,6,8,9-hexahydro-7H-purin-7-yl)acetamide 

Relevant academic research and scientific papers

AMIDES OF HETEROCYCLIC COMPOUNDS AS TRPA1 INHIBITORS

Amides of heterocyclic compounds as Transient Receptor Potential subfamily A (TRPA) modulators are provided In particular, compounds described herein are useful for treating or preventing diseases, conditions and/ or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1) Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. (I).

Radical oxidation of xanthines: A reaction pathway to uric acid?

The reaction of isocaffeine (1,3,9-trimethylxanthine) with oxidizing radicals is studied by using pulse radiolysis techniques to study the transients and follow their transformation kinetics, and by identifying the corresponding stable final products by HPLC. Isocaffeine reacts with OH to yield an hydroxyl adduct at C(8) that leads, after oxidation, to the formation of the corresponding uric acid (1,3,9-trimethyl-8-hydroxyxanthine). Upon reaction with SO4- the formation of the same uric acid was also seen, resulting from the hydration of the radical cation initially formed, followed by oxidation. This result is in contrast with that observed for purines of the adenine system, where a C(8)-hydroxylated derivative is formed upon oxidation by OH but not by SO4-.

Purines. XIV [1]. Synthesis and properties of 8-nitroxanthine and its N- methyl derivatives

Xanthine (1) and its N-methyl derivatives 2-16 have been nitrated to the corresponding 8-nitro derivatives 17-32 under different reaction conditions. Nitration in glacial acetic acid with nitric acid works well with the N-7 unsubstituted and some of the 9-methylxanthines, respectively, whereas the 7- methylxanthine derivatives react best with nitronium tetrafluoroborate in sulfolane or glacial acetic acid. The 8-nitro group can be displaced nucleophilically to form 8-chloro-, 33, 34, 8-ethoxy-, 35, 36, and uric acid derivatives 37-40, respectively. The newly synthesized 8-nitroxanthines have been characterized by elemental analyses, pK-determinations and uv and 1H- nmr spectra.